News

CMN Weekly (7 January 2022) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - Jan. 7, 2022

Top Picks

Research

Industry

Detection

  • American researchers have developed a highly sensitive CRISPR-Cas12a immuno-assay to detect CXCL9 in urine from kidney transplant patients. CXCL9 in the urine is a biomarker for acute rejection episodes, but it isn't easy to detect with traditional ELISA assays. The new immuno-CRISPR assay used anti-CXCL9 antibody-DNA barcode conjugates and amplified fluorescent signals via Cas12a-based trans-cleavage activity of FQ reporter substrates. As a result, a detection limit of 14 pg/mL of CTXL9 was achieved, equivalent to a ~7-fold increase compared to ELISA.

Reviews

Huh, Huh, Wow

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (7 January 2022) - Your Weekly CRISPR Medicine News
Search your next CRISPR job here...
Search your next CRISPR job here...
CLINICAL TRIALS
IND Enabling
Phase I
Phase II
Phase III
T-cell Acute Lymphoid Leukaemia, ALL, (NCT05397184)
Sponsors:
Great Ormond Street Hospital for Children NHS Foundation Trust
Indicator
IND Enabling
Phase I
Phase II
Phase III
Solid tumors, (NCT05361174)
Sponsors:
Iovance Biotherapeutics, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine